Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-05-16
2006-05-16
Balasubramanian, Venkataraman (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C546S290000, C546S297000
Reexamination Certificate
active
07045538
ABSTRACT:
The present invention generally relates to nicotinic compounds, in the form of aryl substituted olefinic compounds, as well as pro-drug, N-oxide, metabolite and pharmaceutically acceptable salt forms thereof. Methods of modulating neurotransmitter release via administration of the compounds, pro-drugs, N-oxides and/or pharmaceutically acceptable salts are also disclosed.
REFERENCES:
patent: 4927838 (1990-05-01), Guthrie et al.
patent: 5212188 (1993-05-01), Caldwell et al.
patent: 5283363 (1994-02-01), Kuhnt et al.
patent: 5356906 (1994-10-01), Ciganek et al.
patent: 5585388 (1996-12-01), Cosford et al.
patent: 5597919 (1997-01-01), Dull et al.
patent: 5604231 (1997-02-01), Smith et al.
patent: 5616707 (1997-04-01), Crooks et al.
patent: 5616716 (1997-04-01), Dull et al.
patent: 5629325 (1997-05-01), Lin et al.
patent: 5663356 (1997-09-01), Ruecroft et al.
patent: 5723477 (1998-03-01), McDonald et al.
patent: 5726316 (1998-03-01), Crooks et al.
patent: 5731314 (1998-03-01), Bencherif et al.
patent: 5811442 (1998-09-01), Bencherif et al.
patent: 5824692 (1998-10-01), Lippiello et al.
patent: 5861423 (1999-01-01), Caldwell et al.
patent: 6218383 (2001-04-01), Bencherif
patent: 6232316 (2001-05-01), Dull et al.
patent: 6262124 (2001-07-01), Dull et al.
patent: 6274606 (2001-08-01), Caldwell
patent: 6455554 (2002-09-01), Dull et al.
patent: 6489349 (2002-12-01), Bencherif et al.
patent: 6492399 (2002-12-01), Dull et al.
patent: 6531606 (2003-03-01), Dull et al.
patent: 6603011 (2003-08-01), Caldwell et al.
patent: 0 559 495 (1993-09-01), None
patent: WO 96/20600 (1996-07-01), None
patent: WO 96/20929 (1996-07-01), None
patent: WO 96/31475 (1996-10-01), None
patent: WO 96/36637 (1996-11-01), None
patent: WO 97/40011 (1997-10-01), None
patent: WO 98/37071 (1998-08-01), None
Cooper, Donald A. et al.,Biological Mass Spectrometry, vol. 22, pp. 590-594 (1993).
Loffler, Karl et al.,Chem. Ber., vol. 42, pp. 3431-3488 (1909).
LaForge, F.B.,J.Am. Chem. Soc, vol. 50, pp. 2477-2483 (1928).
Pinner, A.,Chem. Ber., pp. 2861-2870 (1894).
Malek, N. et al.,J.Org. Chem., vol. 47, pp. 5395-5397 (1982).
Joyce, N.J. et al.,Heterocycles, vol. 29, No. 7, pp. 2947-2949 (1978).
Frank, W. et al.,J. Org. Chem., vol. 43(15), pp. 2947-2949 (1978).
Sprouse, C. et al., Abstracts of Papers, p. 32, Coresta/TCRC, Joint Conference (1972).
Pinner, A.,Chem. Ber., pp. 1053-1061 (1894).
Acheson, R. et al.,J. Chem. Soc. Perkin Trans., vol. 2, pp. 579-585 (1980).
Bleicher, Leo et al.,Synlett, pp. 1115-1116 (1995).
Lippiello, P. et al.,JPET, vol. 279, No. 3, pp. 1422-1429 (1996).
Bencherif, M. et al.,JPET, vol. 279, No. 3, pp. 1413-1421 (1996).
Hogberg, Thomas, et al., Homallylic Amines Related to Zimeldine. A Comparative Study on Neuronal Seroonin and Norepinephrine Reuptake Based on Conformational Analysis;J. Med. Chem., vol. 31, (1988); pp. 913-919; XP00000000608983.
International Search Report; Nov. 26, 1999; R.J. Reynolds Tobacco Company, et al.; PCT/US99/12340; file ref: 627-311.WO.
S. Arneric & M. Williams, “Nicotinic Agonists in Alzheimer's Disease: Does the Molecular Diversity of Nicotine Receptors Offer the Opportunity for Developing CNS-Selective Cholinergic Channel Activators?”Int. Acad. Biomed. Drug Res., 7: 58-70 (1994).
Bencherif et al., “Metanicotine: A Nicotinic Agonist with CNS Selectivity—In Vitro Characterization,”Society for Neuroscience Abstracts, 21(1-3): 605 (1995).
Perry et al., “Alteration in Nicotine Binding Sites in Parkinson's Disease, Lewy Body Dementia and Alzheimer's Disease: Possible Index of Early Neuropathology,”Neuroscience, 64(2): 385-395 (1995).
B. Sahakian & J. Coull, “Nicotine and Tetrahydroaminoacradine: Evidence for Improved Attention in Patients with Dementia of the Alzheimer Type,”Drug Development Research, 31: 80-88 (1994).
Wilson Jr. et al., “Nicotine-Like Actions of cis-Metanicotine and trans-Metanicotine,”The Journal of Pharmacology and Experimental Therapeutics, 196(3): 685-696 (1976).
Segal, M., and JM Auerbach, “Muscarinic receptors involved in hippocampal plasticity,”Life Sci., 60(13-14): 1085-91 (1997).
Bencherif Merouane
Bhatti Balwinder S.
Caldwell William S.
Crooks Peter A.
Dull Gary M.
Balasubramanian Venkataraman
Targacept, Inc.
Womble Carlyle Sandridge & Rice PLLC
LandOfFree
Compounds capable of activating cholinergic receptors does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compounds capable of activating cholinergic receptors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compounds capable of activating cholinergic receptors will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3557056